Decitabine
Decitabine (Dacogen) is an infusion that loosens the chemical silencing of genes in myelodysplastic syndromes and acute myeloid leukaemia, helping the bone marrow work again. An oral version combined with cedazuridine has its own record.
Overview
Decitabine was approved by the FDA in 2006 for myelodysplastic syndromes of all FAB subtypes and IPSS intermediate-1, intermediate-2 and high-risk groups, on a randomised trial of 170 patients in which decitabine plus supportive care produced responses and delayed progression to AML compared with supportive care alone. The EU authorised Dacogen in 2012 for newly diagnosed AML in adults aged 65 and over not eligible for standard induction (DACO-016). It is the hypomethylating partner for venetoclax in unfit AML alongside azacitidine, and the oral fixed-dose combination decitabine-cedazuridine (Inqovi, 2020) delivers equivalent exposure. Myelosuppression is universal early in treatment and responses typically take four to six cycles.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2006 | Myelodysplastic syndromes, all FAB subtypes and IPSS intermediate-1 to high risk |
| EU | 2012 | Newly diagnosed de novo or secondary AML in adults 65 and over not candidates for standard induction |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Decitabine" OR ABSTRACT:"Decitabine" OR TITLE:"Dacogen" OR ABSTRACT:"Dacogen" OR TITLE:"5-aza-2'-deoxycytidine" OR ABSTRACT:"5-aza-2'-deoxycytidine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decitabine, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductBusulfan
Shares Otsuka Pharmaceutical and the tag nci-list.
- ProductVorinostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag nci-list.
- ProductMitoxantrone
Shares Acute myeloid leukaemia and the tag nci-list.
- ProductThioguanine
Shares Acute myeloid leukaemia and the tag nci-list.
- ProductRasburicase
Shares Acute myeloid leukaemia and the tag nci-list.
- ProductIdarubicin
Shares Acute myeloid leukaemia and the tag nci-list.
- ProductCytarabine
Shares Acute myeloid leukaemia and the tag nci-list.
- ProductDaunorubicin
Shares Acute myeloid leukaemia and the tag nci-list.